Overview

Comprehensive genomic profiling of solid tumors has moved beyond single-driver reports toward broad panels that capture hundreds of genes at once. A 410-gene solid tumor assay is designed to map the full alteration landscape of a tumor, giving oncologists the co-alterations they need to build rational combination regimens rather than treating one mutation in isolation. The wider the gene set, the more relationships between pathways become visible in a single report.

From Profile to Combination Strategy

Many effective regimens pair a targeted agent with a second hit on the same pathway or with an immunotherapy backbone. A 410-gene report can reveal, for example, concurrent receptor tyrosine kinase activation and downstream RAS or PI3K signaling, or loss of DNA-repair competence that predicts sensitivity to platinum or PARP inhibition. Seeing these relationships together helps a molecular tumor board choose a combination that attacks the tumor on two fronts instead of one, and avoid combinations whose targets are already bypassed.

Companion and Complementary Testing

Broad panels often report genes whose alterations are linked to approved companion diagnostics, such as those guiding EGFR, ALK, or BRCA-directed therapy. Because no single assay covers every modality, the 410-gene result is usually read alongside complementary tests like PD-L1 immunohistochemistry and mismatch-repair or microsatellite-status assessment. The panel's job is to triage which complementary tests are worth ordering next, saving time and tissue while keeping the treatment plan evidence-linked.

Reporting Actionability Tiers

The clinical usefulness of a broad panel depends on how findings are ranked. A strong report separates tier-one alterations with approved matched therapy, tier-two alterations with trial or compendia support, and variants of uncertain significance that should not drive therapy. For the laboratory buyer, a clear actionability tiering and a cited knowledge base are what turn a long variant list into a decision aid that oncologists will actually adopt.

Operational Fit for Reference Laboratories

For the laboratory buyer, a 410-gene panel is a throughput decision as much as a scientific one. Hybrid-capture or amplicon workflows differ in turnaround, input requirement, and failure rate on low-quality samples. Validated wet-lab and bioinformatics pipelines, plus a report that ranks variants by actionability, determine whether the panel integrates smoothly into an existing oncology service or becomes a bottleneck that delays care.

FAQ

Q: How does a 410-gene panel support combination therapy decisions? A: It reveals co-alterations across pathways so a team can pair agents that hit the same axis twice or combine targeted and immunotherapy backbones.

Q: Does the panel report tumor mutational burden or microsatellite status? A: Many comprehensive panels include tumor mutational burden and microsatellite instability in their scope, but buyers should confirm the exact metrics each report delivers.

Q: Which tumor types are covered by the assay? A: It is intended for solid tumors broadly, providing a tumor-agnostic alteration map that complements site-specific guidelines.